CHF5993 pMDI with HFA-152a

Phase 2

Chiesi Farmaceutici S.p.A.

CHF5993 pMDI with HFA-152a is one of 27 therapeutic programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AsthmaRecruiting

AsthmaPhase 2

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

CHF5993 pMDI with HFA-152a

Chiesi Farmaceutici S.p.A.

Phase 2

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Asthma

NCT07301736

Clinical

Trials by Indication[1]

Asthma1 trial

A Phase II Multinational, Multicentre, Double-blind, Randomised, Active-controlled, 3-way Cross-over Study to Evaluate the Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a Versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in Subjects With Mild to Moderate Asthma

Recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT07301736·780 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CHF5993 pMDI with HFA-152a. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CHF5993 pMDI with HFA-152a. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Chiesi Farmaceutici S.p.A.

CHF5993 pMDI with HFA-152a

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News